Physician profile
Caleb Robert Howard
NPI 1962061663
$2,284.82
in general payments reported to CMS, 2019-2025
14 companies · $335 in 2025
The $335 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $387 · 2022: $335 · 2023: $312 · 2024: $916 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $830 · Consulting Fee: $718 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.70 |
| Consulting Fee | $717.50 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $777.21 | 2024-2025 | Spevigo, Anzupgo, Adbry |
| Janssen Biotech, INC. | $563.29 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $193.99 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $107.62 | 2021 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Depuy Synthes Sales INC. | $92.43 | 2025 | Va-Lcp |
| Sun Pharmaceutical Industries INC. | $89.99 | 2022 | |
| Galderma Laboratories, L.P. | $87.63 | 2024-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $78.58 | 2023-2025 | Sotyktu |
| Organon LLC | $56.10 | 2025 | |
| Novartis Pharmaceuticals Corporation | $52.52 | 2021 | |
| Genzyme Corporation | $52.05 | 2021-2025 | |
| Strata Skin Sciences, INC. | $18.15 | 2022 | |
| Pfizer INC. | $15.27 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.